BioPharma Dive

MARCH 27, 2023

Vertex will license CRISPR technology to develop insulin-producing islet cells that are more resistant to immune rejection, adding to other efforts directed at Type 1 diabetes.

Diabetes 117

Diabetes Immunity Immunization 117

European Pharmaceutical Review

NOVEMBER 18, 2022

Tzield (teplizumab-mzwv), the first drug to help prolong the onset of stage 3 type 1 diabetes in adults and children over eight years old with stage 2 type 1 diabetes, has been approved by the US Food and Drug Administration (FDA). The drug binds to certain immune system cells and delays progression to stage 3 type 1 diabetes.

Diabetes 98

Diabetes Immunity Immunization 98

Digital Pharmacist

OCTOBER 25, 2023

November is American Diabetes Month – a time to come together to spread awareness about diabetes prevention and management. In this blog post, we’ll explore key ways pharmacies can actively participate in American Diabetes Month.

Diabetes 105

Diabetes Medication Therapy Management (MTM) Immunity Immunization 105

STAT

AUGUST 21, 2024

… A new observational study found that people taking Ozempic and Wegovy appeared to experience suicidal thoughts at a higher rate than people on other drugs, though experts raised concerns about the methodology and the findings contradict what some other studies have found about the class of GLP-1 diabetes and obesity drugs , STAT writes.

Diabetes 261

Diabetes Immunity Immunization 261

European Pharmaceutical Review

DECEMBER 7, 2023

Results from a world-first human trial, published in the New England Journal of Medicine , has shown that a drug called baricitinib has promise as the first disease-modifying treatment of its kind for type 1 diabetes, that can be administered as a tablet. 

Diabetes 111

Diabetes Immunity Immunization 111

pharmaphorum

MARCH 11, 2021

Vertex Pharma has made its name with treatment for cystic fibrosis, but has big plans in cell and genetic therapies – and has just chalked up fast-track status from the FDA for a cell-based therapy for diabetes. . The aim is to replace the pancreatic tissue that is damaged by the autoimmune reaction that underlies type 1 diabetes.

Diabetes 98

Diabetes Immunity Immunization 98

European Pharmaceutical Review

JUNE 27, 2023

Lonza and Vertex Pharmaceuticals Incorporated have agreed to collaborate to support the manufacture of Vertex’s Type 1 diabetes cell therapy portfolio. It is delivered by an infusion into the hepatic portal vein and requires chronic immunosuppressive therapy to protect the islet cells from immune rejection.

Diabetes 98

Diabetes Immunity Immunization 98

Pharmaceutical Business Review

JANUARY 9, 2025

It works by restoring organ-specific immune tolerance without conceding systemic immunity. These cells then migrate to the site of tissue inflammation, where they work to restore immune tolerance. These assets can activate in vivo generation of antigen-specific Treg cells thereby stopping and curing autoimmune disease.

Immunity 97

Immunity Immunization Diabetes 97

STAT

FEBRUARY 28, 2024

vaccination policy when Mandy Cohen, director of the Centers for Disease Control and Prevention, signs off on the recommendation from the Advisory Group on Immunization Practices. Babies infected around the time of birth, adults 65 and older and people with heart disease, diabetes or high blood pressure are at higher risk of severe disease.

Vaccines 285

Vaccines Diabetes Immunity Immunization 285

STAT

OCTOBER 8, 2024

Food and Drug Administration for a “reckless and arbitrary” decision to remove a widely prescribed Eli Lilly drug for combating diabetes and obesity from an official shortages list , STAT tells us. … A trade group representing large compounding pharmacies has sued the U.S.

Compounding 246

Compounding Compounding Pharmacies Vaccines Immunity 246

World Pharma News

NOVEMBER 12, 2024

Immune cells are capable of detecting infections just like a sniffer dog, using special sensors known as Toll-like receptors, or TLRs for short. The approach that they took might help to speed up the search for drugs to combat infectious diseases, cancer, diabetes or dementia.

Immunity 73

Immunity Immunization Diabetes Hospitals 73

STAT

MAY 17, 2024

It’s an overreaction of the immune system. Novo Nordisk is “optimistic” that a fire at a construction site in Kalundborg, Denmark, a key manufacturing hub, will not delay its plans to boost production capacity of its popular weight loss drug Wegovy and Ozempic for diabetes , Reuters reports.

Diabetes 263

Diabetes Immunity Immunization 263

Pharmaceutical Technology

JANUARY 10, 2023

On November 17, 2022, the FDA approved Provention Bio’s Tzield (teplizumab) , making it the first and only treatment to delay the onset of type 1 diabetes (T1D). Tzield’s approval brings the opportunity to explore how the drug can advance diabetes education, treatment, and management. “We Equity in early-stage testing.

Diabetes 98

Diabetes Immunity Immunization Communication 98

Pharmaceutical Technology

AUGUST 13, 2024

GLP-1RAs may be more effective for patients with immune diseases and type 2 diabetes than DPP-4 inhibitors, as per analysed health records.

Diabetes 105

Diabetes Immunization Immunity 105

NY Times

NOVEMBER 27, 2021

A new treatment using stem cells that produce insulin has surprised experts and given them hope for the 1.5 million Americans living with the disease.

Diabetes 145

Diabetes Immunization Immunity 145

pharmaphorum

AUGUST 17, 2020

Phase 3 development in the bleeding disease thrombocytopenia is expected to begin by the end of the year as long as COVID-19 does not impact on trials and there is also an ongoing phase 2 development programme in various other immune diseases.

Immunity 124

Immunity Immunization Diabetes 124

pharmaphorum

JULY 11, 2022

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The post Vertex buys diabetes cell therapy rival ViaCyte for $320m appeared first on.

Diabetes 59

Diabetes Immunity Immunization 59

Express Pharma

NOVEMBER 21, 2024

This innovation is designed to treat Community-Acquired Bacterial Pneumonia (CABP), a severe illness caused by drug-resistant bacteria, which disproportionately affects vulnerable populations, including children and the elderly as well as immune-compromised hosts like patients with diabetes, cancers etc.

Diabetes 105

Diabetes Immunity Immunization 105

pharmaphorum

NOVEMBER 18, 2022

At its second attempt, Provention Bio has secured FDA approval for teplizumab, as a treatment to delay late-stage type 1 diabetes (T1D) in at-risk individuals – becoming the first disease-modifying therapy for these patients. The post Provention finally gets FDA nod for type 1 diabetes drug teplizumab appeared first on.

Diabetes 52

Diabetes Immunity Immunization 52

Express Pharma

APRIL 7, 2023

The findings, published in the journal Environmental Health Perspectives , provide further evidence on the adverse effects of air pollution on the immune system. However, the role of long-term exposure to air pollution on hybrid immunity (infection plus vaccination) deserves further investigation, they added.

Vaccines 110

Vaccines Immunity Immunization Diabetes 110

pharmaphorum

JUNE 1, 2021

Novo Nordisk – which is already active in stem cell therapies with a candidate in early development for type 1 diabetes – is on the hook for up to $598 million in total licensing and milestone payments plus royalties on sales if HS-001 reaches the market.

Immunity 138

Immunity Immunization Diabetes 138

Digital Pharmacist

JANUARY 16, 2023

From cancer prevention to diabetes awareness, these events help bring communities together. World Immunization Week: April 24-30. National Immunization Awareness Month. National Diabetes Month. World Immunization Week | Post a flyer and share a list on social media of your vaccination offerings. . UV Safety Month.

Immunity 98

Immunity Immunization Vaccines Diabetes 98

Express Pharma

OCTOBER 16, 2024

Ophelia Chan, Business Fundamentals Senior Analyst at GlobalData, comments, “The COVID-19 pandemic highlighted the key advantages of mRNA technology in vaccine development, including rapid production, precise immune targeting, and streamlined manufacturing- factors that drove the success of mRNA-based COVID-19 vaccines.”

Vaccines 104

Vaccines Immunity Immunization Diabetes 104

Express Pharma

JUNE 9, 2024

Adults with underlying medical conditions, such as chronic obstructive pulmonary disease (COPD), asthma, heart failure and diabetes (3) are at increased risk for severe consequences from an RSV infection compared to those without these conditions. RSV can exacerbate these conditions and lead to pneumonia, hospitalisation or death.(4)

Vaccines 111

Vaccines Immunity Immunization Diabetes 111

pharmaphorum

NOVEMBER 12, 2021

It also takes into account existing and chronic health factors such as diabetes, obesity, and conditions that affect the immune system can play a big role in risk factors related to COVID-19.

Diabetes 135

Diabetes Immunity Immunization 135

Express Pharma

AUGUST 16, 2024

This success was driven by the soaring demand for Lilly’s type 2 diabetes drug Mounjaro, weight loss drug Zepbound and breast cancer drug Verzenio. Novo Nordisk dominated the GLP-1 market with its type 2 diabetes and weight loss drugs, Ozempic and Wegovy, driving a 10.8 billion acquisition of Alpine Immune Sciences.

Diabetes 98

Diabetes Immunity Immunization Vaccines 98

Pharmaceutical Technology

SEPTEMBER 10, 2024

Integrated Nanotherapeutics secured funds to propel the development of an immune tolerizing therapeutic for Type 1 diabetes.

Diabetes 52

Diabetes Immunization Immunity 52

Pharmacy Times

OCTOBER 28, 2024

Investigators found that electronic letter reminders were most effective for older individuals, those who were unvaccinated in the preceding season, those with cardiovascular disease, and those with diabetes.

Immunity 37

Immunity Immunization Diabetes Vaccines 37

pharmaphorum

JANUARY 17, 2022

It prevents the overstimulation of the immune system and is said to improve survival and reduce the need for ventilation in covid-19 patients, with no observed increase in adverse effects. Baricitinib, administered with corticosteroids, was strongly recommended as a treatment for patients with severe or critical illness.

Hospitals 116

Hospitals Diabetes Immunity Immunization 116

pharmaphorum

JANUARY 11, 2021

Cambridge-based Kymab is one of several rising stars on the UK biotech scene, with technology that uses transgenic mice to develop antibodies optimised for the human immune system. KY1005 works by bonding to the OX40-Ligand (OX40-L), which forms an important part of the process that activates the immune system.

Immunity 76

Immunity Immunization Diabetes Vaccines 76

European Pharmaceutical Review

MARCH 14, 2024

This month, new data from Novo Nordisk has revealed that semaglutide could become the first GLP-1 treatment option for patients with type 2 diabetes and chronic kidney disease (CKD). This leads to the formation of immune complexes that deposit in the glomerulus and result in haematuria, proteinuria, and decline in kidney function.

Diabetes 98

Diabetes Labelling Immunity Immunization 98

European Pharmaceutical Review

MARCH 14, 2024

This month, new data from Novo Nordisk has revealed that semaglutide could become the first GLP-1 treatment option for patients with type 2 diabetes and chronic kidney disease (CKD). This leads to the formation of immune complexes that deposit in the glomerulus and result in haematuria, proteinuria, and decline in kidney function.

Diabetes 98

Diabetes Labelling Immunity Immunization 98

The Thyroid Pharmacist

SEPTEMBER 2, 2022

A review paper published in 2010 that discussed the relationship between thyroid dysfunction and metabolic disorders, highlighted the fact that patients with diabetes were up to three times more likely to develop a thyroid disorder. (7). Hypoglycemia is an early risk factor for developing diabetes. Type 2 Diabetes.

Diabetes 98

Diabetes Health and Personal Care Stores Immunity Immunization 98

Pharmaceutical Technology

OCTOBER 25, 2022

As proof-of-concept (PoC), chronic immune-mediated diseases such as atopic dermatitis (AD) and inflammatory bowel disease (IBD) will be the focus areas of the preliminary model. For the project, deep datasets and capabilities of Sanofi will be leveraged to potentially transform the practice of medicine using digital data and AI.

Drug Development 98

Drug Development Diabetes Immunity Immunization 98

pharmaphorum

FEBRUARY 16, 2021

In 2019, Novartis also bought into the category via a $310 million takeover of IFM Therapeutics, which is developing NLRP3 drugs for atherosclerosis and non-alcoholic steatohepatitis (NASH), while UK startup NodThera raised $55 million last year for its own NLRP3 programme, eyeing NASH and diabetes.

Diabetes 119

Diabetes Immunity Immunization 119

Express Pharma

APRIL 24, 2023

Adults above 50 years of age and those suffering from chronic conditions such as diabetes, heart disease and kidney diseases are at an increased risk of developing shingles because of weakened immunity. Vaccination is the only effective preventive option.”

Vaccines 97

Vaccines Diabetes Immunity Immunization 97

Pharmaceutical Technology

APRIL 3, 2023

The latest guidance applies to the current phase of the pandemic and reflects the impact of the Omicron variant, which has led to high levels of immunity in all age groups through both vaccination efforts and infections across the globe.

Vaccines 111

Vaccines Diabetes Immunity Immunization 111